KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

Source :: Business Wire. September 3, 2024
Publication Year :: 2024
Abstract: - If approved, sebetralstat will be the first, oral on-demand treatment for HAE - - FDA PDUFA goal date of June 17, 2025 - CAMBRIDGE, Mass. & SALISBURY, England -- [...]

Subjects :: United States. Food and Drug Administration
Drugs -- Prescribing
Children -- Health aspects
Kallikrein
Angioneurotic edema -- Drug therapy
Business
Business, international

Tools